<DOC>
	<DOC>NCT01363440</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) on the best corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in patients with diabetic macular edema (DME) with central involvement.</brief_summary>
	<brief_title>Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<criteria>The following is an abbreviated list of inclusion criteria: Adults ≥ 18 years with type 1 or 2 diabetes mellitus Decrease in vision determined to be primarily the result of DME in the study eye BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye The following is an abbreviated list of exclusion criteria: Laser photocoagulation (panretinal or macular) in the study eye within 90 days of day 1 Previous use of intraocular or periocular corticosteroids in the study eye within 120 days of day 1 Previous treatment with antiangiogenic drugs in the study eye (pegaptanib sodium, bevacizumab, ranibizumab, etc.) within 90 days of day 1 Active proliferative diabetic retinopathy (PDR) in the study eye Uncontrolled diabetes mellitus Only 1 functional eye even if that eye is otherwise eligible for the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Diabetic Macular Edema</keyword>
	<keyword>Diabetic Retinopathy</keyword>
</DOC>